Skip to main content
OpenTrials
Completed

NCT Number: NCT04309123

Pilot Study of TransAeris® System in Surgical Patients at Risk of Prolonged Mechanical Ventilation

This study will be conducted as a pilot trial of the TransAeris system for the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD) in patients identified prior to surgery to be at greater risk of prolonged mechanical ventilation (PMV).

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States

About this study

This pilot study is an open label observational study in adult open cardiac surgery patients. Eligible patients from whom informed consent is obtained and electrodes are successfully implanted are enrolled in the study. All subjects will be implanted with the TransLoc electrodes during their primary surgery. Following admission to the ICU, diaphragm EMG recording will begin and continue until TransAeris use begins or until discharge from the ICU. TransAeris stimulation therapy adjunctive to continued MV will begin 24 hours after leaving the operating room. TransAeris stimulator settings (stimulus intensity, stimulus frequency, and burst on/off) will be programmed to optimize diaphragm recruitment without compromising patient comfort.

When deemed ready by the physician, the subject will perform a spontaneous breathing trial (SBT). Diaphragm EMG will be recorded for the first 15 minutes of an SBT, when performed with study staff available, then TransAeris therapy will continue. If an SBT is not performed on a day or performed when study staff is not available, a diaphragm EMG will be recorded for 15 minutes and then TransAeris therapy will be resumed. If the subject fails the SBT or the physician determines the subject is inappropriate for extubation, TransAeris stimulation therapy will continue. Prior to leaving the ICU, diaphragm EMG will be recorded for 15 minutes and the TransLoc electrodes will be removed. Subjects that reach Day 30 after implantation will stop TransAeris therapy. Diaphragm EMG will be recorded for 15 minutes and the TransLoc electrodes will be removed prior to the end of Day 30.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is undergoing an open cardiac procedure by median sternotomy
  • Subject is at risk of prolonged mechanical ventilation ≥ 24H
  • Subject is at least 22 years of age
  • Informed consent has been obtained from the subject or designated representative

Exclusion criteria

  • Subject is on invasive mechanical ventilation prior to procedure
  • Subject has known or pre-existing phrenic nerve paralysis
  • Subject has progressive, non-reversible neuromuscular disease affecting the diaphragm
  • Subject is pregnant or lactating
  • Subject is actively participating in another clinical study which could affect outcomes in this study

Treatment and study plan

TransAeris System

Device

The TransAeris System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).

Primary outcomes

  1. Adverse Events

    Time frame: 60 Days

    Incidence of Serious Device Related Adverse Events

Secondary outcomes

  1. Duration on Mechanical Ventilation

    Time frame: 30 Days

    Time on Mechanical Ventilation

Sponsors and collaborators

Lead sponsor

Synapse Biomedical

Industry

Registry information

Acronym: TRANSITION

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 16, 2020
Registry last updated
Apr 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.